Chapter review

Fitzgerald PMHNP board review. ch08. Mood Disorders. This is drive 5 of 8. When I say Pause. Answer. wait, then I will give the answer. New section. Bipolar and related disorders: criteria, mixed features, rapid cycling, mania vs hypomania. Topic. Sample Question 126: Bipolar II Definition. Bottom Line. - **Bipolar II disorder** requires at least one **major depressive episode** lasting at least 2 weeks and at least one **hypomanic episode** lasting at least 4 consecutive days. - A lifetime history of even one full **manic episode** permanently excludes the diagnosis of **bipolar II disorder** and establishes **bipolar I disorder**. - **Hypomania** is defined by an elevated, expansive, or irritable mood with increased goal-directed activity and at least 3 **DIGFAST** symptoms (4 if mood is irritable only) for at least 4 days, causing an unequivocal change in functioning without marked social or occupational impairment, hospitalization, or **psychosis**. - **Bipolar II disorder** has a lifetime prevalence of 1.2% in the general population and is more prevalent in females than males, with a mean age of onset between 21 and 24 years. - **First-line** pharmacotherapy for acute bipolar depression includes **quetiapine**, **lurasidone**, **lumateperone**, **lamotrigine**, or **lithium**. - Antidepressant monotherapy is contraindicated in **bipolar II disorder** due to the high risk of inducing mood switching into hypomania or mania, as well as rapid cycling. Must Know for Boards. Diagnostic Criteria and Timelines. - **Major depressive episode requirement**: Must meet full DSM-5-TR criteria for at least 2 weeks, including at least 5 of 9 **SIGECAPS** symptoms with depressed mood or anhedonia. - **Hypomanic episode requirement**: Must persist for at least 4 consecutive days with elevated or irritable mood plus 3 or 4 **DIGFAST** symptoms. - **Exclusion criterion**: Zero lifetime history of full **manic episodes**. Clinical Differentiators. - **Functioning**: **Hypomania** causes an observable change in behavior, but does not cause marked social or occupational impairment. - **Hospitalization**: Need for psychiatric hospitalization automatically classifies the episode as **mania**, resulting in a diagnosis of **bipolar I disorder**. - **Psychotic features**: Presence of **delusions** or **hallucinations** automatically defines the episode as **mania**, making the diagnosis **bipolar I disorder**. Epidemiology and Genetics. - **Prevalence**: Lifetime prevalence is 1.2% for **bipolar II disorder** and 1.5% for **bipolar I disorder**, with the overall bipolar spectrum reaching up to 6%. - **Gender distribution**: **Bipolar II disorder** affects females more frequently than males, whereas **bipolar I disorder** affects males and females equally. - **Heritability**: First-degree relatives of individuals with bipolar disorder have a 5% to 10% risk, which increases to 40% to 50% among monozygotic twins. Exam Signposts. - **First-line**: Evidence-based treatments for bipolar depression in **bipolar II disorder** are **quetiapine** (target 300 mg daily at bedtime), **lurasidone**, **lumateperone**, **lamotrigine** (slowly titrated to prevent **Stevens-Johnson syndrome**), or **lithium**. - **Safety alert**: Suicide risk in **bipolar II disorder** is extremely high during major depressive episodes and mixed states, requiring continuous safety and lethality assessments. - **Board trap**: Prescribing SSRI monotherapy to a depressed patient without screening for past hypomania. Antidepressant monotherapy can trigger mood switching, rapid cycling (4 or more mood episodes in 12 months), or treatment resistance. Compare and Distinguish. **Bipolar II Disorder** vs. **Bipolar I Disorder**. - **Think**: **Bipolar II** is hypomania plus major depression. **Bipolar I** is full mania (major depression is common but not required for diagnosis). - **Priority**: Evaluate for any history of psychiatric hospitalization, **psychosis**, or severe impairment in daily life. - **Boards are testing**: Remembering that a single episode of full **mania** defines **bipolar I disorder** forever, regardless of how many depressive or hypomanic episodes occur. **Bipolar II Disorder** vs. **Unipolar Major Depressive Disorder**. - **Think**: Unipolar depression has no history of elevated mood or hypomania. - **Priority**: Administer the **Mood Disorder Questionnaire** (**MDQ**) or perform a careful longitudinal history to unmask hidden hypomanic periods. - **Boards are testing**: Identifying **bipolar II disorder** in patients who report non-response, agitation, or rapid mood shifts when placed on standard antidepressants. **Bipolar II Disorder** vs. **Cyclothymic Disorder**. - **Think**: **Cyclothymia** is chronic, fluctuating hypomanic and depressive symptoms for at least 2 years in adults (1 year in children) that never meet full criteria for a **major depressive episode**. - **Priority**: Verify whether the patient has ever met full **SIGECAPS** criteria for a 2-week **major depressive episode**. - **Boards are testing**: Distinguishing subthreshold mood swings (**cyclothymia**) from full **bipolar II disorder**. Sample Questions. Question 1. The patient with bipolar disorder who is most likely to be misdiagnosed as having unipolar depression most likely has: - A. **Dysthymia** - B. **Bipolar II disorder** - C. **Bipolar I disorder** - D. **Cyclothymic disorder** Pause. Answer: B. **Why it is correct**: Patients with **bipolar II disorder** almost exclusively seek psychiatric evaluation during major depressive episodes because **hypomania** feels pleasant, highly productive, or normal to the patient. Because patients rarely complain of hypomanic states, clinicians routinely miss the hypomanic history and incorrectly diagnose unipolar **major depressive disorder**. **Why the other choices are wrong**: - A. **Dysthymia** (persistent depressive disorder) is a unipolar condition involving chronic depressed mood for at least 2 years without any hypomanic or manic episodes. - C. **Bipolar I disorder** features full **manic episodes** that cause severe functional disruption, **psychosis**, or emergency hospitalization, making the manic history obvious and difficult to miss. - D. **Cyclothymic disorder** involves chronic, fluctuating mood swings over 2 years that never meet full criteria for a **major depressive episode**. **Test-taking pearl**: When a question stem describes a depressed patient who failed multiple SSRIs or experienced severe agitation on antidepressants, suspect hidden **bipolar II disorder**. **Concept tested**: Clinical presentation and diagnostic misclassification of **bipolar II disorder**. Question 2. Jeremy, a 36-year-old married attorney, was referred by his primary care provider for a consultation regarding his depression. He relates problems with what he calls minor depression and mood swings for at least 15 years. He denies ever having any suicidal ideation, hospitalization, or legal difficulty. On the Mood Disorder Questionnaire, he checks four items positive and three as possibly positive. Which disorder most likely fits his symptoms? - A. **Bipolar I disorder** - B. **Bipolar II disorder** - C. **Cyclothymic disorder** - D. **Dysthymia** Pause. Answer: C. **Why it is correct**: Jeremy presents with a 15-year history of chronic, low-grade depressive symptoms and fluctuating mood swings that have never caused severe functional disruption, hospitalization, or legal issues. Because his symptoms are chronic (exceeding 2 years) and subthreshold without meeting full criteria for a **major depressive episode** or **manic episode**, **cyclothymic disorder** is the correct diagnosis. **Why the other choices are wrong**: - A. **Bipolar I disorder** requires at least one full **manic episode** causing marked impairment, **psychosis**, or hospitalization. - B. **Bipolar II disorder** requires at least one fully met **major depressive episode** lasting at least 2 weeks alongside a **hypomanic episode**. - D. **Dysthymia** (persistent depressive disorder) involves chronic low-grade depression without hypomanic mood elevation or cyclic mood swings. **Test-taking pearl**: Long-standing mood instability without full major depressive episodes or full manic episodes points directly to **cyclothymic disorder**. **Concept tested**: Differential diagnosis of **cyclothymic disorder** versus **bipolar II disorder**. Next. Topic. Sample Question 127: DIGFAST Components. Bottom Line. * **Bipolar I disorder** requires at least 1 manic episode lasting 7 consecutive days or requiring hospitalization, characterized by elevated, expansive, or irritable mood plus increased goal-directed activity. * **Bipolar II disorder** requires at least 1 major depressive episode lasting 2 weeks and at least 1 hypomanic episode lasting at least 4 consecutive days, with no lifetime history of mania. * The **DIGFAST** mnemonic defines manic and hypomanic symptoms: Distractibility, Indiscretion, Grandiosity, Flight of ideas, Activity increase, Sleep deficit, and Talkativeness. * Diagnosis of mania or hypomania requires mood elevation plus goal-directed energy, along with at least 3 **DIGFAST** symptoms, or 4 symptoms if the mood is only irritable. * **Rapid cycling** specifier requires 4 or more distinct mood episodes within a 12-month period. * **First-line** pharmacotherapy for acute euphoric mania is **lithium** or a second-generation antipsychotic, while **valproate** is preferred for dysphoric mania, mixed features, or comorbid substance use. * **Safety alert.** Antidepressants used as monotherapy in bipolar disorder can induce acute mania or accelerate rapid cycling and must be tapered and discontinued during manic episodes. * **Board trap.** Patients with **bipolar II disorder** are frequently misdiagnosed with unipolar depression because they present for care during depressive episodes and do not report productive hypomanic periods. DIGFAST Mnemonic and Diagnostic Criteria. The **DIGFAST** acronym outlines the core symptom cluster required to diagnose manic and hypomanic episodes under DSM-5-TR: * **D**istractibility: Attention is easily drawn to irrelevant outside stimuli. * **I**ndiscretion: Excessive involvement in activities with high potential for painful consequences, such as buying sprees, sexual indiscretions, or foolish business investments. * **G**randiosity: Inflated self-esteem or grandiose beliefs, ranging from exaggerated self-confidence to frank delusions of special status or divine mission. * **F**light of ideas: Subjective experience that thoughts are racing or rapid continuous speech with abrupt topic switches. * **A**ctivity increase: Increased goal-directed activity at work, school, socially, or psychomotor agitation like pacing or restlessness. * **S**leep deficit: Decreased need for sleep, such as feeling fully rested after only 2 or 3 hours of sleep. * **T**alkativeness: More talkative than usual or feeling intense pressure to keep talking. A formal diagnosis of mania or hypomania requires a core mood change (elevated, expansive, or irritable mood) accompanied by persistently increased goal-directed activity or energy, plus at least 3 **DIGFAST** symptoms. If the mood is only irritable, at least 4 **DIGFAST** symptoms are required. Mania versus Hypomania. Use this contrast framework to distinguish manic episodes from hypomanic episodes on exam questions: Concept: Mania * **Timeline:** Lasts at least 1 week, or any duration if hospitalization is required. * **Symptom threshold:** Elevated mood plus increased activity, plus 3 or more **DIGFAST** symptoms, or 4 if mood is irritable. * **Impairment:** Causes marked impairment in social or occupational functioning, or necessitates hospitalization to prevent harm, or exhibits psychotic features. * **First-line:** **Lithium**, **valproate**, **carbamazepine**, or second-generation antipsychotics like **quetiapine**, **olanzapine**, or **risperidone**. Concept: Hypomania * **Timeline:** Lasts at least 4 consecutive days. * **Symptom threshold:** Same 3 or 4 **DIGFAST** symptoms as mania. * **Impairment:** Causes an unequivocal change in functioning observable by others, but is not severe enough to cause marked occupational impairment, does not require hospitalization, and never features psychosis. * **First-line:** **Lithium**, **valproate**, or second-generation antipsychotics. Never use antidepressant monotherapy. Mixed Features and Rapid Cycling. * **Mixed features:** Criteria are met for a manic or hypomanic episode, and at least 3 depressive symptoms are present simultaneously during the majority of days. Alternatively, a major depressive episode presents with at least 3 manic or hypomanic symptoms. * **Rapid cycling:** The occurrence of 4 or more mood episodes (major depressive, manic, or hypomanic) within a 12-month period. * **Board trap.** Prescribing antidepressant monotherapy in patients with mixed features or rapid cycling accelerates episode frequency and worsens mood instability. **Valproate** or **lithium** combined with an antipsychotic is the correct choice. Clinical Safety and Exam Signposts. * **Safety alert.** Unopposed antidepressant therapy in bipolar spectrum disorders can trigger manic conversion or rapid cycling. Antidepressants must be tapered and discontinued when manic symptoms emerge. * **Safety alert.** A patient on maintenance mood stabilizer therapy should have a manic fire drill plan. Keep a short supply of a second-generation antipsychotic like **olanzapine** 5 to 10 mg or **quetiapine** on hand so the patient can start taking it at the first sign of sleep loss and racing thoughts while contacting the PMHNP. * **First-line.** Classical euphoric mania responds best to **lithium**. Dysphoric or irritable mania, mixed features, rapid cycling, or comorbid substance use responds best to **valproate**. Sample Board Practice Questions. Question 1. Jeremy, a 36-year-old married attorney, is referred for consultation regarding minor depression and mood swings lasting at least 15 years. He denies suicidal ideation, psychiatric hospitalizations, or legal problems. On the Mood Disorder Questionnaire, he checks 4 items positive and 3 items as possibly positive. Which disorder most likely fits his symptoms? A) Bipolar I disorder B) Bipolar II disorder C) Cyclothymic disorder D) Dysthymia Pause. Answer. C. Why it is correct: Cyclothymic disorder involves chronic mood fluctuations for at least 2 years in adults (1 year in adolescents), featuring hypomanic and depressive symptoms that never meet full criteria for hypomania or major depressive episodes, without severe functional disruption or hospitalization. Why the other choices are wrong: * **A:** Bipolar I disorder requires at least 1 full manic episode lasting 7 days or requiring hospitalization. * **B:** Bipolar II disorder requires at least 1 full major depressive episode lasting 2 weeks and at least 1 full hypomanic episode lasting 4 days. * **D:** Dysthymia (persistent depressive disorder) involves chronic depressed mood for 2 years without any hypomanic or manic symptoms. Question 2. A patient with bipolar disorder who is most likely to be misdiagnosed as having unipolar major depressive disorder most likely has: A) Dysthymia B) Bipolar II disorder C) Bipolar I disorder D) Cyclothymic disorder Pause. Answer. B. Why it is correct: Bipolar II disorder involves major depressive episodes that bring the patient to clinical attention, while hypomanic episodes feel pleasurable and productive, causing patients to omit them during clinical evaluation unless specifically questioned. Why the other choices are wrong: * **A:** Dysthymia is chronic unipolar depression without any hypomanic or manic episodes. * **C:** Bipolar I disorder features overt manic episodes causing marked impairment or hospitalization, making mania easy to identify. * **D:** Cyclothymic disorder features mild mood swings without full major depressive episodes, so patients do not present with classic unipolar depression. 💡 Would you like to review the psychopharmacology of mood stabilizers like lithium and valproate next? Next. New section. First-line treatment, monitoring, contraindications, and black box warnings. Topic. Bipolar Depression Treatment. Bottom Line Summary. * **First-line** monotherapy options for acute **bipolar depression** include **quetiapine** at 300 mg daily, **lurasidone**, **lumateperone**, **lamotrigine**, or **lithium**. * Antidepressant monotherapy is strictly contraindicated in **bipolar depression** due to the high risk of precipitating acute mania, hypomania, or rapid cycling. * When an antidepressant is required, it must be paired with a mood stabilizer or an atypical antipsychotic, such as the **olanzapine-fluoxetine combination**. * **Lithium** and **clozapine** are the only two psychiatric medications with proven, independent anti-suicide effects in patients with **bipolar disorder**. * Target therapeutic serum **lithium** levels are 0.8 to 1.2 mEq/L for acute episodes and 0.6 to 1.0 mEq/L for maintenance, measured as a 12-hour trough level after 4 days of consistent dosing. * **Lamotrigine** requires no baseline laboratory monitoring but demands a slow, 5-week dose titration starting at 25 mg daily for 2 weeks to prevent life-threatening **Stevens-Johnson syndrome**. * Nonsteroidal anti-inflammatory drugs like **ibuprofen**, ACE inhibitors like **lisinopril**, and thiazide diuretics impair renal clearance and significantly increase **lithium** toxicity risk. * In lactating mothers, **lithium** is classified as Hale's Lactation Risk Category L4 (hazardous) and is contraindicated during breastfeeding. High-Yield Concepts and Pharmacotherapy Strategy. First-Line Treatment Selection and Severity Matching. Treating **bipolar depression** presents a unique clinical challenge because misdiagnosing it as unipolar depression and initiating antidepressant monotherapy can trigger a switch into mania. * **First-line** monotherapy agents for acute **bipolar depression** include **quetiapine** at a target dose of 300 mg daily, **lurasidone**, **lumateperone**, **lamotrigine**, and **lithium**. * Combination therapy using the **olanzapine-fluoxetine combination** is also an evidence-based **first-line** choice when antidepressant coverage is necessary. **Board trap:** Never prescribe antidepressant monotherapy with an SSRI or SNRI for a patient with **bipolar depression**. Antidepressants used without a co-prescribed mood stabilizer or atypical antipsychotic can induce acute mania, hypomania, or rapid cycling. If full manic criteria emerge during antidepressant treatment and persist beyond the expected physiological effect of the drug, the formal diagnosis becomes **bipolar I disorder**. **Safety alert:** If a patient on an antidepressant develops manic or hypomanic symptoms, the provider must immediately taper and discontinue the antidepressant while maintaining or optimizing mood stabilizer therapy. Lithium Pharmacotherapy, Safety Alerts, and Toxicity. **Lithium** remains a cornerstone of acute and maintenance therapy for **bipolar disorder**. * **First-line** indication: **Lithium** is especially effective for classical euphoric or grandiose mania and for preventing recurrent depressive and manic episodes. * Suicide prevention: **Lithium** possesses a proven, independent anti-suicide effect in **bipolar disorder**, reducing completed suicide rates significantly. * Dosing and blood level monitoring: Draw a 12-hour post-dose serum trough level after 4 days on a stable dose. Acute therapeutic levels are 0.8 to 1.2 mEq/L, while maintenance levels are 0.6 to 1.0 mEq/L. * Baseline laboratory requirements: Before starting **lithium**, order serum creatinine, BUN, GFR, TSH, electrolytes, CBC with differential, serum hCG pregnancy test, urinalysis, and an EKG in patients over age 50. * Maintenance lab monitoring: Check creatinine, BUN, GFR, TSH, and a 12-hour trough level every 4 to 8 weeks initially, then every 6 to 12 months in stable patients. **Safety alert:** **Lithium** is strictly contraindicated in acute renal failure, severe dehydration, and sodium depletion. In chronic kidney disease, if the GFR drops below 60 mL/min, the dose must be reduced and monitored closely. **Safety alert:** **Lithium** toxicity begins at serum levels of 1.5 mEq/L, with severe life-threatening toxicity occurring above 2.0 mEq/L. Early signs include lethargy, coarse hand tremor, muscle weakness, nausea, vomiting, and diarrhea. Severe toxicity presents as ataxia, dysarthria, nystagmus, hyperreflexia, altered mental status, cardiac arrhythmias, coma, and death. **Board trap:** Co-prescribing NSAIDs such as **ibuprofen**, ACE inhibitors such as **lisinopril**, or thiazide diuretics reduces renal excretion and precipitates **lithium** toxicity. Corticosteroids like **prednisone** do not alter renal lithium clearance or increase toxicity risk. **Safety alert:** **Lithium** falls into Hale's Lactation Risk Category L4 (hazardous) because it transfers readily into breastmilk, creating a high risk of infant toxicity and fluid-electrolyte instability. Breastfeeding is contraindicated in mothers taking **lithium**. Lamotrigine Titration and Safety Warnings. **Lamotrigine** is an evidence-based **first-line** monotherapy for acute **bipolar depression** and long-term maintenance. * Lab monitoring pearl: **Lamotrigine** does NOT require baseline or routine laboratory monitoring. * Standard titration schedule: Start at 25 mg daily for 2 weeks, increase to 50 mg daily for 2 weeks, then 100 mg daily for 1 week, reaching the standard target maintenance dose of 200 mg daily by week 5. **Safety alert:** Rapid dose escalation or skipping steps during titration increases the risk of severe, life-threatening cutaneous adverse reactions, including **Stevens-Johnson syndrome** and toxic epidermal necrolysis. Patients must be educated to report any new skin rash immediately. Second-Generation Antipsychotics and Combination Regimens. Atypical antipsychotics play a major role in managing **bipolar depression**. * **Quetiapine** at 300 mg daily monotherapy provides robust antidepressant efficacy in **bipolar depression**. * **Lurasidone** and **lumateperone** offer effective monotherapy or adjunctive therapy for **bipolar depression** with a favorable metabolic profile. * **Olanzapine-fluoxetine combination** blends an atypical antipsychotic with an SSRI to safely treat acute **bipolar depression** while protecting against manic switching. **Board trap:** **Olanzapine** and **quetiapine** carry significant risks of metabolic syndrome, including severe weight gain, dyslipidemia, and new-onset diabetes mellitus. Baseline fasting glucose, lipid panel, weight, and BMI must be monitored periodically. Valproate, Carbamazepine, and Refractory Strategies. When **first-line** agents are ineffective or poorly tolerated, alternate mood stabilizers and interventional therapies are utilized. * **Valproate** (divalproex) is preferred for irritable or mixed mania, rapid cycling, co-occurring substance use, or traumatic brain injury. Target therapeutic trough serum levels are 50 to 120 mcg/mL. Baseline labs require liver function tests, CBC with differential and platelets, and serum hCG. Discontinue **valproate** if liver transaminases (AST/ALT) exceed 2 to 3 times the upper limit of normal. * **Carbamazepine** requires baseline liver enzymes, CBC, and genetic screening for the **HLA-B*1502** allele in patients of Asian descent prior to initiation due to high **Stevens-Johnson syndrome** risk. * **Electroconvulsive therapy** is the gold-standard treatment for refractory **bipolar depression**, acute life-threatening suicidality, severe depression during pregnancy, or psychotic depression. Fitzgerald Sample Test Questions. Question 1. Jeremy, a 36-year-old married attorney, was referred by his primary care provider for a consultation regarding his depression. He relates problems with what he would call minor depression and mood swings for at least 15 years. He denies ever having any suicidal ideation, hospitalization, or legal difficulty. On the MDQ, he checks 4 items positive and 3 as possibly positive. Which disorder most likely fits his symptoms? A) Bipolar I disorder B) Bipolar II disorder C) Cyclothymic disorder D) Dysthymia Pause. Answer. C. Why It Is Correct. **Cyclothymic disorder** is characterized by chronic, fluctuating mood disturbances involving periods of hypomanic symptoms and periods of depressive symptoms lasting for at least 2 years in adults. These mood swings cause distress but do not meet full DSM criteria for a major depressive episode or a manic episode, and they have not required hospitalization or caused severe legal or functional collapse. Why the Other Choices Are Wrong. * **A:** **Bipolar I disorder** requires at least one full manic episode, which typically causes severe functional impairment, hospitalization, or psychotic features. * **B:** **Bipolar II disorder** requires at least one full major depressive episode and at least one distinct hypomanic episode, which Jeremy lacks. * **D:** Dysthymia (persistent depressive disorder) involves chronic low-grade depression without periods of hypomanic or elevated mood symptoms. Question 2. The patient with bipolar disorder who is most likely to be misdiagnosed as having unipolar depression most likely has which of the following? A) Dysthymia B) Bipolar II disorder C) Bipolar I disorder D) Cyclothymic disorder Pause. Answer. B. Why It Is Correct. Patients with **bipolar II disorder** are frequently misdiagnosed as having unipolar major depressive disorder because they present for clinical care during painful depressive episodes and rarely report hypomanic episodes. Hypomanic episodes are non-disruptive, brief, or experienced by the patient as periods of high productivity and normal well-being. Why the Other Choices Are Wrong. * **A:** Dysthymia is a primary unipolar depressive disorder, not a form of bipolar disorder. * **C:** **Bipolar I disorder** features full manic episodes that cause overt functional disruption, police contact, or hospitalization, making it easily recognized. * **D:** **Cyclothymic disorder** consists of mild, chronic mood fluctuations that do not meet full criteria for major depressive episodes. Question 3. There is positive evidence that the use of lithium by a breastfeeding woman can pose a risk to the infant. This medication meets Hale's lactation risk category: A) L1 B) L2 C) L3 D) L4 Pause. Answer. D. Why It Is Correct. **Lithium** is classified under Hale's Lactation Risk Category L4 (hazardous) because significant amounts of lithium pass into breastmilk. This creates a substantial risk of infant toxicity, hypothermia, cyanosis, and fluid-electrolyte imbalances, making breastfeeding contraindicated. Why the Other Choices Are Wrong. * **A:** Category L1 represents safest medications with extensive controlled studies showing no infant risk. * **B:** Category L2 represents safer medications studied in a limited number of women without increased risk. * **C:** Category L3 represents moderately safe medications where adverse effects are possible or data is limited. Question 4. Mr. Cooper is treated for bipolar disorder with lithium carbonate. His last serum lithium level was 0.7 mEq/L. Which of the following is NOT a risk factor for developing lithium toxicity? A) Ibuprofen 600 mg daily for joint pain B) Addition of lisinopril to blood pressure regimen C) A change in GFR to less than 60 mL/min/1.73 m2 D) Addition of prednisone for the management of an acute gout attack Pause. Answer. D. Why It Is Correct. **Prednisone** is a corticosteroid that does not decrease renal lithium excretion or alter sodium balance in a manner that increases serum **lithium** levels. Why the Other Choices Are Wrong. * **A:** **Ibuprofen** is an NSAID that reduces renal blood flow and prostaglandin synthesis, decreasing **lithium** excretion and elevating serum levels. * **B:** **Lisinopril** is an ACE inhibitor that promotes sodium excretion, inducing renal reabsorption of **lithium** and causing toxicity. * **C:** A decline in GFR below 60 mL/min impairs renal excretion of **lithium**, leading to accumulation and toxic serum levels. Question 5. Which of the following medications does NOT require initial laboratory testing before implementing therapy? A) Carbamazepine B) Lamotrigine C) Valproate D) Lithium Pause. Answer. B. Why It Is Correct. **Lamotrigine** does not require baseline or initial laboratory testing prior to starting treatment. Prescribing safety is achieved strictly through slow dose titration starting at 25 mg daily to prevent severe cutaneous reactions. Why the Other Choices Are Wrong. * **A:** **Carbamazepine** requires baseline liver function tests, complete blood count with differential, and genetic testing for the **HLA-B*1502** allele in Asian patients. * **C:** **Valproate** requires baseline liver transaminases, CBC with platelet count, and serum pregnancy testing. * **D:** **Lithium** requires comprehensive baseline testing, including serum creatinine, BUN, GFR, TSH, electrolytes, CBC, urinalysis, pregnancy test, and EKG. Next. Topic. FDA Black Box Warning. Bottom Line Summary. * All **antidepressant** classes carry an **FDA black box warning** for an increased risk of **suicidal ideation** and suicidal behavior in children, adolescents, and young adults up to **age 24**. * The warning specifically highlights an increased incidence of **suicidal ideation** and suicidal thoughts, not an increase in completed suicides. * In older adults aged 65 and older, **antidepressant** treatment is associated with a net reduction in suicide risk. * Mandatory clinical safety monitoring requires evaluating patients weekly or biweekly during the initial 4 to 8 weeks of therapy and following any dose modification. * **Fluoxetine** is FDA-approved for **major depressive disorder** in pediatric patients aged 8 and older, while **escitalopram** is approved for ages 12 and older. * **Fluoxetine** possesses a long elimination half-life of 84 hours for the parent drug and 7 to 15 days for its active metabolite, making it forgiving for missed doses, whereas **paroxetine** has a short half-life and carries the highest risk of **discontinuation syndrome**. * Severe **major depressive disorder** requires pharmacotherapy; psychotherapy alone is not an evidence-based first-line treatment for severe depression. High-Yield Concept: FDA Black Box Warning and Antidepressant Safety. The **FDA black box warning** on **antidepressants** is one of the most frequently tested safety topics on PMHNP board certification exams. You must master the exact population boundaries, clinical triggers, and monitoring parameters required by national standards of care. Target Population and Age Cutoffs. The **FDA black box warning** applies to all **antidepressant** medications across all classes, including SSRIs like **fluoxetine**, **sertraline**, **paroxetine**, **citalopram**, **escitalopram**, and **fluvoxamine**; SNRIs like **venlafaxine** and **duloxetine**; NDRIs like **bupropion**; tricyclic antidepressants; and MAOIs. The warning specifically targets children, adolescents, and young adults up to **age 24** (under age 25). **Safety alert:** When initiating an **antidepressant** in any patient under **age 25**, you must establish a structured safety monitoring plan. Plan for weekly or biweekly contact during the first 1 to 2 months of treatment to assess for emerging **suicidal ideation**, severe agitation, restlessness, panic, or unexpected shifts in behavior. **Board trap:** Test writers frequently attempt to mislead candidates by stating that **antidepressants** increase completed suicides in young adults. The exam tests the precise distinction that the **FDA black box warning** is for increased **suicidal ideation** and suicidal thoughts, not completed suicides. Furthermore, do not confuse age tiers: in adults aged 65 and older, **antidepressants** actually exert a protective effect against suicide. Pediatric Approvals and First-Line Selection. **First-line:** **Fluoxetine** is the primary first-line **antidepressant** with FDA approval for **major depressive disorder** in pediatric patients down to age 8. **Escitalopram** holds FDA approval for **major depressive disorder** in adolescents aged 12 and older. In young adults, **sertraline**, **fluoxetine**, and **escitalopram** are preferred first-line agents due to their overall safety and tolerability profiles. Pharmacokinetics, Half-Life, and Discontinuation. When selecting an **antidepressant**, pharmacokinetics dictate clinical safety. **Fluoxetine** has an extended elimination half-life of 2 to 3 days for the parent compound and 7 to 15 days for its active metabolite, norfluoxetine. This long half-life creates a built-in self-taper, making **fluoxetine** ideal for patients with poor medication adherence. Conversely, **paroxetine** and **venlafaxine** have short half-lives and no active long-acting metabolites. Abrupt cessation of short half-life agents triggers **antidepressant discontinuation syndrome**, represented by the mnemonic **FINISH**: * **F:** Flu-like symptoms (fatigue, lethargy, myalgias) * **I:** Insomnia and vivid dreams * **N:** Nausea and gastrointestinal distress * **I:** Imbalance (dizziness, vertigo, ataxia) * **S:** Sensory disturbances (paresthesias, electric shock sensations or brain zaps) * **H:** Hyperarousal (anxiety, agitation, frontal headache) **Discontinuation syndrome** is bothersome and uncomfortable, but it is not life-threatening. To prevent it, taper **antidepressants** gradually over at least 6 weeks when discontinuing treatment. Severity-Based Treatment Selection. Treatment planning depends on diagnostic severity measured by standardized tools like the PHQ-9 or Zung scale. Mild to moderate **major depressive disorder** can be managed with psychotherapy alone, medication alone, or combination therapy. Severe **major depressive disorder** (such as a PHQ-9 score of 20 or higher, or a Zung score of 65 or higher) mandates pharmacotherapy. Psychotherapy alone is contraindicated as a sole initial treatment for severe depression. Board-Style Practice Questions. Question 1. Question: A 28-year-old woman with **major depressive disorder** occasionally skips doses of her daily medication and uses a progestin implant for contraception. Which **antidepressant** is the most appropriate candidate for her care? * A. **Paroxetine** * B. **Amitriptyline** * C. **Fluoxetine** * D. **Phenelzine** Pause. Best answer: C. **Fluoxetine** Why it is correct: **Fluoxetine** has an exceptionally long elimination half-life of 2 to 3 days for the parent compound and 7 to 15 days for its active metabolite norfluoxetine. This long half-life provides a self-tapering buffer that protects against **discontinuation syndrome** when a patient occasionally misses a dose. Why the other choices are wrong: * A. **Paroxetine** has a short half-life and carries the highest risk of severe withdrawal symptoms if doses are missed. * B. **Amitriptyline** is a tricyclic antidepressant with dangerous anticholinergic side effects and lethal overdose risk. * C. Correct choice. * D. **Phenelzine** is a monoamine oxidase inhibitor requiring strict dietary tyramine restrictions and posing high drug interaction risks. Test-taking pearl: Choose **fluoxetine** for patients with poor medication adherence because its long half-life prevents rapid plasma drops and withdrawal. Concept tested: Antidepressant pharmacokinetics and half-life clinical selection. Question 2. Question: A 45-year-old woman started taking standard-dose **sertraline** 1 week ago for **major depressive disorder**. She returns complaining that she does not feel better and has developed an on-and-off frontal headache. Physical and neurological examinations are normal. Which clinical guidance is most appropriate? * A. Immediately discontinue **sertraline** due to adverse neurotoxicity. * B. Increase the **sertraline** dose to achieve rapid therapeutic blood levels. * C. Reassure her that therapeutic onset requires several weeks and frontal headache is a common transient side effect. * D. Switch immediately to **venlafaxine** to target dual neurotransmitter pathways. Pause. Best answer: C. Reassure her that therapeutic onset requires several weeks and frontal headache is a common transient side effect. Why it is correct: **Antidepressants** require a therapeutic lag of 4 to 8 weeks for full response. Mild frontal headaches, nausea, and minor agitation are transient side effects during the first 1 to 2 weeks of SSRI initiation that resolve with continued administration. Why the other choices are wrong: * A. Discontinuing **sertraline** for a mild, expected transient side effect with a normal physical exam is unnecessary and premature. * B. Increasing the dose after only 1 week is premature and will intensify transient side effects before therapeutic efficacy can be evaluated. * C. Correct choice. * D. Switching medication classes after 1 week is improper because a full therapeutic trial requires 4 to 8 weeks at a target dose. Test-taking pearl: Counsel patients on transient initiation side effects like headache or nausea and allow a full 4 to 8 week trial before declaring treatment failure. Concept tested: SSRI onset lag time and management of transient initiation side effects. Question 3. Question: A 28-year-old man taking **paroxetine** 20 mg daily for 6 weeks shows no clinical improvement for **major depressive disorder**, maintaining a severe Zung depression score of 65. Which of the following management plans is NOT recommended? * A. Increase the dosage of **paroxetine**. * B. Continue **paroxetine** and initiate evidence-based psychotherapy. * C. Discontinue **paroxetine** and initiate psychotherapy as sole treatment. * D. Switch to a therapeutic dose of **venlafaxine**. Pause. Best answer: C. Discontinue **paroxetine** and initiate psychotherapy as sole treatment. Why it is correct: Psychotherapy alone is not recommended for severe **major depressive disorder** (a Zung score of 65 indicates severe depression). Severe depression requires pharmacotherapy, either as monotherapy or combined with psychotherapy. Why the other choices are wrong: * A. Raising the **paroxetine** dose is an acceptable initial strategy to optimize pharmacotherapy after 6 weeks of minimal response. * B. Combining an **antidepressant** with psychotherapy is a gold-standard approach for severe depression. * C. Correct choice because this option is NOT recommended. * D. Switching to an SNRI like **venlafaxine** is an appropriate second-line strategy when an initial SSRI trial fails. Test-taking pearl: Psychotherapy alone is effective for mild to moderate depression, but severe depression mandates pharmacotherapy. Concept tested: Treatment selection based on depressive severity. Question 4. Question: A 22-year-old man with type 1 diabetes mellitus and **generalized anxiety disorder** has been successfully treated for recurrent **major depressive disorder** with **sertraline**. Having been symptom-free for 6 months, he asks to stop his medication. You advise that he faces a high risk of recurrence due to which factor? * A. Younger age of onset and recurrent episode history * B. Co-occurring **generalized anxiety disorder** * C. Presence of a chronic medical condition * D. All of the above factors Pause. Best answer: D. All of the above factors Why it is correct: **Major depressive disorder** recurrence risk is significantly heightened by a history of multiple prior episodes, early age of onset, co-occurring psychiatric conditions like **generalized anxiety disorder**, and comorbid physical medical illnesses like type 1 diabetes. Why the other choices are wrong: * A. While true, options B and C also independently increase recurrence risk. * B. While true, options A and C also independently increase recurrence risk. * C. While true, options A and B also independently increase recurrence risk. * D. Correct choice because all listed factors collectively elevate long-term recurrence risk and justify maintenance therapy. Test-taking pearl: Identify cumulative recurrence risk factors to determine when a patient requires long-term maintenance **antidepressant** therapy. Concept tested: Risk factors for major depressive disorder recurrence. Question 5. Question: A PMHNP is educating a patient about potential risks associated with stopping **antidepressant** medication abruptly. How is **antidepressant discontinuation syndrome** best characterized? * A. Potentially life-threatening emergency requiring immediate ICU admission * B. Bothersome but non-life-threatening syndrome resolving over time * C. A reaction seen exclusively with long half-life agents like **fluoxetine** * D. A high-risk seizure state requiring anticonvulsant prophylaxis Pause. Best answer: B. Bothersome but non-life-threatening syndrome resolving over time Why it is correct: **Antidepressant discontinuation syndrome** causes uncomfortable symptoms like sensory zaps, flu-like aches, and dizziness, but it is not life-threatening and typically remits within 1 to 2 weeks or resolves upon restarting and slowly tapering the drug. Why the other choices are wrong: * A. **Discontinuation syndrome** is uncomfortable and bothersome, not a life-threatening medical emergency. * B. Correct choice. * C. **Discontinuation syndrome** occurs most severely with short half-life drugs like **paroxetine** and **venlafaxine**, whereas long half-life agents like **fluoxetine** self-taper. * D. Seizures are characteristic of abrupt alcohol or benzodiazepine withdrawal, not standard SSRI discontinuation. Test-taking pearl: Taper **antidepressants** over 6 weeks to prevent **discontinuation syndrome**, and remember that short half-life drugs pose the highest withdrawal risk. Concept tested: Antidepressant discontinuation syndrome characteristics and half-life relationship. Next. End of this drive.